![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/08/06/2925417/0/en/Olema-Oncology-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/15/2882291/0/en/Olema-Oncology-Announces-Promising-New-Data-for-Palazestrant-in-Combination-with-Ribociclib-Presented-at-the-2024-ESMO-Breast-Cancer-Congress.html
https://www.globenewswire.com/news-release/2024/05/08/2878169/0/en/Olema-Oncology-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/08/2877691/0/en/Olema-Oncology-Announces-New-Clinical-Data-for-Palazestrant-in-Combination-with-Ribociclib-to-be-Presented-at-the-2024-ESMO-Breast-Cancer-Annual-Congress.html
https://www.globenewswire.com//news-release/2024/03/06/2841269/0/en/Olema-Oncology-Announces-Publication-of-Data-Highlighting-Palazestrant-s-Ability-to-Inhibit-Wild-Type-and-Mutant-ER-Breast-Cancer-Both-as-Monotherapy-and-in-Combination-with-CDK4-6.html
https://www.globenewswire.com/news-release/2023/12/05/2791260/0/en/Olema-Oncology-Announces-Palazestrant-Demonstrates-Attractive-Combinability-with-CDK4-6-Inhibitors-Ribociclib-and-Palbociclib-in-Phase-1b-2-Studies.html
https://www.globenewswire.com//news-release/2023/11/28/2787398/0/en/Olema-Oncology-to-Present-New-Palazestrant-Clinical-Data-in-Combination-with-CDK4-6-Inhibitors-at-the-2023-San-Antonio-Breast-Cancer-Symposium-SABCS.html
https://www.globenewswire.com//news-release/2023/10/22/2764320/0/en/Olema-Oncology-Announces-Positive-Phase-2-Monotherapy-Clinical-Study-Results-for-Palazestrant.html